Cannabinoids and Immunotherapy: Friends or Foes?

Cannabinoids, compounds found in cannabis, have been the subject of research regarding immunotherapy in cancer treatment. Recent study indicates that they may destroy tumor cells; however, these compounds can also influence tumor growth through the Endocannabinoid System (ECS). The relationship is complex, but researchers emphasize that different factors need to be evaluated with greater precision.

Immunotherapy and ECS: Allies or Adversaries? 

The ECS is composed of cannabinoid receptors, endocannabinoids, and enzymes, playing an important role in homeostasis and tissue protection. Immunotherapy, on the other hand, is an approach that unleashes immune system cells to combat tumors. 

The combination of the two treatments, according to the study, indicates that cannabinoids, especially THC, may impair antitumor immunity and reduce the effectiveness of cancer therapy. 

“Inflammation is a risk factor for tumorigenesis, but an active immune system is a weapon against tumor development,” states the study. It also highlights that immunotherapy, while effective, faces challenges such as resistance and low response rates. 

Researchers also emphasize that the ECS may play a fundamental role in tumor growth, but more research is needed to evaluate this relationship. 

In summary, while cannabinoids offer promise in understanding cancer and improving immunotherapy, the complexity of their influence on the ECS and the tumor microenvironment (TME) demands a deeper exploration of existing studies and the conduct of further research. The balance between potential benefits and possible harmful effects needs to be carefully assessed to determine the exact role of cannabinoids in cancer immunotherapy.